Research Article Details
| Article ID: | A20297 |
| PMID: | 26040363 |
| Source: | Nutr Hosp |
| Title: | Effect of the intake of liquids rich in polyphenols on blood pressure and fat liver deposition in rats submitted to high-fat diet. |
| Abstract: | INTRODUCTION: Seeking better quality of life, the number of studies on functional foods and disease prevention is growing fast. Whole red grape juice (WRGJ) and red wine (RW) stand out, which are rich in polyphenols, showing antioxidant and anti-inflammatory activity. OBJECTIVE: To evaluate the effect of WRGJ and RW intake and resveratrol solution (RS) on blood pressure and fat liver deposition of rats fed with high-fat diet. MATERIAL AND METHODS: During 60 days, 50 Rattus norvegicus Wistar Albino adults were divided into: control group (CG)--balanced diet, hyperlipidic group (HG), red wine group (RWG), grape juice group (JGG) and resveratrol group (RG)--hyperlipidic diet. Feed and water were offered ad libttum to all groups. WRGJ, RW and RS were offered daily to JG, WG and RG, respectively. Blood pressure was measured using tail plestimograph. The animals were anesthetized, sacrificed and the liver was removed, weighed and fat was extracted using Soxhlet extractor. RESULTS: No difference in weight gain, feed intake, liver weight and diastolic blood pressure among groups was observed. However, systolic blood pressure (mmHg) and liver fat concentration (g%) were lower (p<0.05) in JGG than in HG, WG and RG, but similar to CG. CONCLUSIONS: The daily consumption of WRGJ minimizes the effects of high-fat diet on systolic blood pressure and prevents nonalcoholic fatty infiltration in the liver of animals, which was not observed in the consumption of RW or resveratrol solution. |
| DOI: | 10.3305/nh.2015.31.6.8655 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D301 | Resveratrol | Chemical drug | DB02709 | ALOX15; ALOX5; AHR; NR1I2; NR1I3 | Anticancer agent | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |